Recombinant RSV live vaccine strain and the preparing method thereof
US12304929B2 · kind B2 · utility
0Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2022 |
| Grant date | May 20, 2025 |
| Priority date | — |
| Expiry date | Apr 11, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/20222
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a recombinant attenuated respiratory syncytial virus (RSV) comprising F protein of stabilized pre-fusion RSV, or comprising protein consisting of the amino acid sequence represented by SEQ ID NO: 2 or functional fragment thereof, and provides genome of the recombinant RSV and a recombinant vector comprising the genome. The recombinant attenuated RSV can be provided as a live vaccine strain which maintains infectability and has excellent safety and stability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.